Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

导出原文传递

翻译打印收藏纠错

作者： Sabatine, Marc S. ^[1] ; Giugliano, Robert P. ^[2] ; Keech, Anthony ^[3] ; Honarpour, Narimon ^[4] ; Wang, Huei ^[5] ; Liu, Thomas ; Wasserman, Scott M. ; Scott, Robert ; Sever, Peter S. ; Pedersen, Terje R.

作者单位： Univ London Imperial Coll Sci Technol & Med, Int Ctr Circulatory Hlth, London, England ^[1] Univ Sydney, NHMRC Clin Trials Ctr, Sydney Med Sch, Sydney, NSW 2006, Australia ^[2] Oslo Univ Hosp, Ulleval, Norway ^[3] Amgen Inc, Thousand Oaks, CA USA ^[4] Brigham & Womens Hosp, Div Cardiovasc Med, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA ^[5]

发布时间 2017-07-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

The American heart journal

2016年173卷

94-101页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

The American heart journal

相似文献

The American heart journal

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

The American heart journal

相似文献

The American heart journal

相关期刊

检索历史清除